Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209750 | 0.99 | ALDH1A1 (0.71) | ALDH1A1TSHRHPGDLMNANPSR1 | |
| SCHEMBL24210125 | 0.99 | ALDH1A1 (0.71) | ALDH1A1TSHRHPGDLMNANPSR1 | |
| SCHEMBL24209738 | 0.90 | GAA (0.68) | ALDH1A1TSHRHPGDLMNASMN1; SMN2 | |
| SCHEMBL24209789 | 0.90 | ALDH1A1 (0.61) | ALDH1A1TSHRHPGDLMNANPSR1 | |
| SCHEMBL24209735 | 0.88 | ALDH1A1 (0.58) | ALDH1A1TSHRHPGDLMNANPSR1 | |
| SCHEMBL24209736 | 0.87 | ALDH1A1 (0.58) | ALDH1A1TSHRHPGDLMNANPSR1 | |
| SCHEMBL25334790 | 0.87 | ALDH1A1 (0.67) | ALDH1A1TSHRHPGDKMT2ACRHBP | |
| SCHEMBL22016331 | 0.86 | ALDH1A1 (0.70) | ALDH1A1TSHRHPGDLMNAKMT2A | |
| SCHEMBL24209629 | 0.84 | ALDH1A1 (0.54) | ALDH1A1TSHRHPGDLMNANPSR1 | |
| SCHEMBL25937563 | 0.83 | ALDH1A1 (0.66) | ALDH1A1TSHRHPGDLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
| EP-3653208-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | Fundación Profesor Novoa Santos (ES) | 2020-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | ALDH1A1 1206/4885TSHR 4635/4885HPGD 2761/4885 |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | ALDH1A1 967/4885TSHR 4382/4885HPGD 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.